BAM
CASC

Burnham Asset Management’s Cascadian Therapeutics, Inc. CASC Stock Holding History

Burnham Asset Management’s Portfolio CASC Stock Details CASC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		$10K Buy
+1,833
New +$12.4K ﹤0.01% 202

Other funds holding CASC

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
EAM
EverPoint Asset Management Stamford, Connecticut $5.38B AUM 21.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Burnham Asset Management's CASC Position: Q2 2016 in Review

Burnham Asset Management opened a new position in Cascadian Therapeutics, Inc. (CASC) in Q2 2016: 1,833 shares worth $10K. The stake represents ﹤0.01% of the portfolio and ranks #202 among its holdings.

75 funds tracked by Wall St. Rank hold CASC as of Q2 2016.

  • Burnham Asset Management held 1,833 shares of Cascadian Therapeutics, Inc. worth $10K as of Q2 2016.
  • Cascadian Therapeutics, Inc. was a new Burnham Asset Management position in Q2 2016.
  • Cascadian Therapeutics, Inc. made up ﹤0.01% of Burnham Asset Management's portfolio in Q2 2016, its #202 holding.
  • 75 funds tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q2 2016.

Based on Burnham Asset Management's 13F filing for Q2 2016, filed 12 Aug 2016.